Moderna, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of Moderna, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times Moderna, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Moderna, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 2.2× / 5.0× / 9.9× | 35.7× | revenue $1.9 B | $4.3 B to $19.2 B | 84 |
| Price to book | 3.1× / 4.5× / 12.9× | 10.4× | book equity $8.7 B | $26.5 B to $111.5 B | 69 |
Against its own history
Moderna, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
Price to sales
40.5×Now above its median of 4.2×, in the top quarter of its range; range 2.1× to 689.0× over 30 months.
Price to book
10.4×Now above its median of 1.8×, in the top quarter of its range; range 0.8× to 35.2× over 30 months.
As of Oct 30, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $1.9 B | $-2.8 B | $-1.9 B | $192 M | $-2.1 B | $-2.0 B | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $3.2 B | $-3.6 B | $-3.0 B | $1.1 B | $-4.1 B | $-1.9 B | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $6.8 B | $-4.7 B | $-3.1 B | $707 M | $-3.8 B | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $19.3 B | $8.4 B | $5.0 B | $400 M | $4.6 B | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $18.5 B | $12.2 B | $13.6 B | $284 M | $13.3 B | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $803 M | $-747 M | $2.0 B | $68 M | $2.0 B | — | SEC annual report (10-K, 20-F) |